Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.
Sutherland KA, Parry CM, McCormick A, Kapaata A, Lyagoba F, Kaleebu P, Gilks CF, Goodall R, Spyer M, Kityo C, Pillay D, Gupta RK; DART Virology Group. Sutherland KA, et al. PLoS One. 2015 Sep 18;10(9):e0137834. doi: 10.1371/journal.pone.0137834. eCollection 2015. PLoS One. 2015. PMID: 26382239 Free PMC article. Clinical Trial.
Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa.
Sutherland KA, Goodall RL, McCormick A, Kapaata A, Lyagoba F, Kaleebu P, Thiltgen G, Gilks CF, Spyer M, Kityo C, Pillay D, Dunn D, Gupta RK; DART Virology Group; DART Trial Team. Sutherland KA, et al. AIDS Res Hum Retroviruses. 2015 Oct;31(10):1032-7. doi: 10.1089/aid.2015.0138. Epub 2015 Aug 10. AIDS Res Hum Retroviruses. 2015. PMID: 26258548 Free PMC article.
Correction: Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.
Sutherland KA, Parry CM, McCormick A, Kapaata A, Lyagoba F, Kaleebu P, Gilks CF, Goodall R, Spyer M, Kityo C, Pillay D, Gupta RK; DART Virology Group. Sutherland KA, et al. PLoS One. 2016 Jun 2;11(6):e0157094. doi: 10.1371/journal.pone.0157094. eCollection 2016. PLoS One. 2016. PMID: 27254277 Free PMC article.
Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study.
Dolling DI, Dunn DT, Sutherland KA, Pillay D, Mbisa JL, Parry CM, Post FA, Sabin CA, Cane PA; UK HIV Drug Resistance Database (UKHDRD); UK Collaborative HIV Cohort Study (UK CHIC). Dolling DI, et al. Among authors: sutherland ka. J Antimicrob Chemother. 2013 Oct;68(10):2339-43. doi: 10.1093/jac/dkt199. Epub 2013 May 27. J Antimicrob Chemother. 2013. PMID: 23711895 Free PMC article.
A G1-like state allows HIV-1 to bypass SAMHD1 restriction in macrophages.
Mlcochova P, Sutherland KA, Watters SA, Bertoli C, de Bruin RA, Rehwinkel J, Neil SJ, Lenzi GM, Kim B, Khwaja A, Gage MC, Georgiou C, Chittka A, Yona S, Noursadeghi M, Towers GJ, Gupta RK. Mlcochova P, et al. Among authors: sutherland ka. EMBO J. 2017 Mar 1;36(5):604-616. doi: 10.15252/embj.201696025. Epub 2017 Jan 25. EMBO J. 2017. PMID: 28122869 Free PMC article.
31 results